Literature DB >> 26293049

Accuracy of Inpatient International Classification of Diseases, Ninth Revision, Clinical Modification Coding for Cytomegalovirus After Kidney Transplantation.

C A Q Santos1, D C Brennan2, M A Olsen3.   

Abstract

BACKGROUND: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding for cytomegalovirus (CMV) has been used as a proxy for active CMV infection or disease occurring in the inpatient setting in retrospective studies of kidney transplant recipients using large amounts of administrative data. However, the accuracy of inpatient CMV coding has not been determined.
METHODS: We identified 393 kidney transplant recipients who were readmitted to Barnes-Jewish Hospital in St. Louis, Missouri from January 1, 2007 to December 31, 2011 to determine the accuracy of the ICD-9-CM diagnosis code for CMV (078.5) in identifying active CMV infection or disease (asymptomatic viremia, CMV syndrome, or tissue-invasive CMV disease) in the inpatient setting, using microbiological, histopathologic, or ophthalmologic evidence for CMV as the gold standard.
RESULTS: The sensitivity and positive predictive value of CMV coding in identifying active CMV infection or disease were 0.77 and 0.71, respectively. The specificity and negative predictive value were both 0.98. The sensitivity of CMV coding in identifying CMV syndrome or tissue-invasive CMV disease was 0.93.
CONCLUSIONS: CMV coding had good accuracy in identifying active CMV infection or disease among readmitted kidney transplant recipients in our hospital. Further validation studies of CMV coding in other hospitals are needed to obtain more generalizable estimates of the accuracy of CMV coding.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26293049      PMCID: PMC4547363          DOI: 10.1016/j.transproceed.2015.04.087

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  15 in total

1.  Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Authors:  Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Mark D Pescovitz
Journal:  Am J Transplant       Date:  2004-04       Impact factor: 8.086

2.  The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Authors:  A Humar; Y Lebranchu; F Vincenti; E A Blumberg; J D Punch; A P Limaye; D Abramowicz; A G Jardine; A T Voulgari; J Ives; I A Hauser; P Peeters
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

3.  Cytomegalovirus in solid organ transplantation.

Authors:  R R Razonable; A Humar
Journal:  Am J Transplant       Date:  2013-03       Impact factor: 8.086

4.  Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation.

Authors:  D Blyth; I Lee; K D Sims; L B Gasink; T D Barton; V M Van Deerlin; P Pfeiffenberger; E A Blumberg
Journal:  Transpl Infect Dis       Date:  2012-01-20       Impact factor: 2.228

Review 5.  New developments in the management of cytomegalovirus infection after solid organ transplantation.

Authors:  Albert J Eid; Raymund R Razonable
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

Review 6.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

7.  Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.

Authors:  A A Boudreault; H Xie; R M Rakita; J D Scott; C L Davis; M Boeckh; A P Limaye
Journal:  Transpl Infect Dis       Date:  2011-03-17       Impact factor: 2.228

8.  Epidemiology and risk factors for late infection in solid organ transplant recipients.

Authors:  C Cervera; M Fernández-Ruiz; A Valledor; L Linares; A Antón; M Ángeles Marcos; G Sanclemente; I Hoyo; F Cofán; M J Ricart; F Pérez-Villa; M Navasa; T Pumarola; A Moreno
Journal:  Transpl Infect Dis       Date:  2011-04-27       Impact factor: 2.228

9.  Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis.

Authors:  I Helanterä; L Kyllönen; I Lautenschlager; K Salmela; P Koskinen
Journal:  Am J Transplant       Date:  2010-09       Impact factor: 8.086

10.  Hospitalizations for cytomegalovirus disease after renal transplantation in the United States.

Authors:  Kevin C Abbott; Iman O Hypolite; Rebecca Viola; Ronald K Poropatich; Paul Hshieh; David Cruess; Clifton A Hawkes; Lawrence Y Agodoa
Journal:  Ann Epidemiol       Date:  2002-08       Impact factor: 3.797

View more
  4 in total

1.  Risk of Noninfectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database.

Authors:  Lucia Sobrin; Yinxi Yu; Gayatri Susarla; Weilin Chan; Tian Xia; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek
Journal:  Ophthalmology       Date:  2020-04-27       Impact factor: 12.079

2.  Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database.

Authors:  Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-05-29       Impact factor: 3.535

3.  Risk of Non-infectious Uveitis with Metformin Therapy in a Large Healthcare Claims Database.

Authors:  Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek
Journal:  Ocul Immunol Inflamm       Date:  2021-03-08       Impact factor: 3.728

4.  Development of Phenotyping Algorithms for the Identification of Organ Transplant Recipients: Cohort Study.

Authors:  Lee Wheless; Laura Baker; LaVar Edwards; Nimay Anand; Kelly Birdwell; Allison Hanlon; Mary-Margaret Chren
Journal:  JMIR Med Inform       Date:  2020-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.